LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-5 (Canceled)

6 (Currently Amended) The method of claim [4] 25, wherein said ~~compound~~ antisense oligonucleotide comprises ~~a~~ DNA ~~oligonucleotide~~.

7 (Currently Amended) The method of claim [4] 25, wherein said ~~compound~~ antisense oligonucleotide comprises ~~a~~ RNA ~~oligonucleotide~~.

8 (Currently Amended) The method of claim [4] 25, wherein said ~~compound comprises a~~ antisense oligonucleotide is chimeric ~~oligonucleotide~~.

9-13 (Canceled)

14 (Currently Amended) The method of claim 25, wherein said ~~compound has~~ antisense oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase.

15 (Currently Amended) The method of claim ~~25~~ 14, wherein said ~~compound has at least one~~ modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

16 (Currently Amended) The method of claim ~~25~~ 14, wherein said ~~compound has at least one~~ modified internucleoside linkage is phosphorothioate internucleoside linkage.

17 (Currently Amended) The method of claim ~~25~~ 14, wherein said ~~compound has at least one~~ modified nucleobase is a 5-methylcytosine.

18-21 (Canceled)

22 (Currently Amended) The method of claim 25, wherein said ~~compound~~ antisense oligonucleotide comprises an antisense nucleic acid molecule that is specifically hybridizable with a coding region of ~~a nucleic acid molecule encoding apolipoprotein(a)~~ SEQ ID NO: 4.

23-24 (Canceled)

25 (Currently Amended) A method of inhibiting the expression of apolipoprotein(a) ~~SEQ ID NO: 4~~ in a cell or tissue, said method comprising ~~:(i)~~ contacting said cell or tissue with ~~a non-cleaving~~ an antisense ~~compound 15 to 30~~ oligonucleotide 12 to 30 nucleobases in length targeted to ~~a nucleic acid molecule encoding said apolipoprotein(a), wherein said compound is at least 70% complementary to said nucleic acid molecule encoding apolipoprotein(a)~~ SEQ ID NO: 4, wherein said antisense oligonucleotide does not substantially inhibit plasminogen, and wherein said ~~compound~~ antisense oligonucleotide inhibits the expression of apolipoprotein(a) mRNA by at least 10% ~~; and~~

~~(ii) determining said inhibited expression of said apolipoprotein(a) SEQ ID NO: 4 in said cell or tissue~~.

26-29 (Canceled)

30 (Currently Amended) A method of treating ~~an animal~~ a human having a disease or condition treatable by the reduction of ~~associated with~~ apolipoprotein(a) ~~SEQ ID NO: 4~~ , said method comprising

~~(i)~~ administering to said ~~animal~~ human a therapeutically ~~or prophylactically~~ effective amount of ~~a non-cleaving~~ an antisense ~~compound 15 to 30~~ oligonucleotide 12 to 30 nucleobases in length targeted to ~~a nucleic acid molecule encoding said apolipoprotein(a), wherein said compound is at least 70% complementary to said nucleic acid molecule encoding apolipoprotein(a)~~ SEQ ID NO: 4, wherein said antisense oligonucleotide does not substantially inhibit plasminogen, and wherein said ~~compound~~ antisense oligonucleotide inhibits the expression of apolipoprotein(a) mRNA by at least 10% ~~; and~~

~~(ii) determining said inhibited expression of said apolipoprotein(a) SEQ ID NO: 4 in said cell or tissue~~.

31 (Canceled)

32 (Previously Presented) The method of claim 30, wherein the disease or condition is a cardiovascular disorder, atherosclerosis, hypercholesterolimia, coronary artery disease or any

combination thereof.

33-39 (Canceled)

40 (New) The method of claim 25, wherein said antisense oligonucleotide is fully complementary to a portion of SEQ ID NO: 4.

41 (New) The method of claim 25, wherein said antisense oligonucleotide is targeted to a sequence within the range of nucleotides 174-203 of SEQ ID NO: 4.

42 (New) The method of claim 25, wherein said antisense oligonucleotide is fully complementary to a sequence within the range of nucleotides 174-203 of SEQ ID NO: 4.

43 (New) The method of claim 25, wherein said antisense oligonucleotide comprises at least an 8 nucleobase portion of SEQ ID NO: 11.

44 (New) The method of claim 25, wherein said antisense oligonucleotide comprises SEQ ID NO: 11.

45 (New) The method of claim 30, wherein said antisense oligonucleotide is fully complementary to a portion of SEQ ID NO: 4.

46 (New) The method of claim 30, wherein said antisense oligonucleotide is targeted to a sequence within the range of nucleotides 174-203 of SEQ ID NO: 4.

47 (New) The method of claim 30, wherein said antisense oligonucleotide is fully complementary to a sequence within the range of nucleotides 174-203 of SEQ ID NO: 4.

48 (New) The method of claim 30, wherein said antisense oligonucleotide comprises at least an 8 nucleobase portion of SEQ ID NO: 11.

49 (New) The method of claim 30, wherein said antisense oligonucleotide comprises SEQ ID NO: 11.

50 (New) The method of claim 30, wherein said antisense oligonucleotide comprises DNA.

51 (New) The method of claim 30, wherein said antisense oligonucleotide comprises RNA.

52 (New) The method of claim 30, wherein said antisense oligonucleotide is chimeric.

53 (New) The method of claim 30, wherein said antisense oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase.

54 (New) The method of claim 53, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

55 (New) The method of claim 53, wherein said modified internucleoside linkage is a phosphorothioate internucleoside linkage.

56 (New) The method of claim 53, wherein said modified nucleobase is a 5-methylcytosine.

57 (New) The method of claim 25, wherein said antisense oligonucleotide comprises at least 3 nucleotide mismatches as compared to the nucleotide sequence encoding human plasminogen.

58 (New) The method of claim 30, wherein said antisense oligonucleotide comprises at least 3 nucleotide mismatches as compared to the nucleotide sequence encoding human plasminogen.

59 (New) The method of claim 30, further comprising a step of measuring lipoprotein(a) levels in the serum of said patient.